Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A15 | Q9H2J7 | 13/20 | 0.82 |
| ▸ | HRH1 | P35367 | 7/20 | 0.82 |
| ▸ | FNTA | P49354 | 5/20 | 0.82 |
| ▸ | FNTB | P49356 | 5/20 | 0.82 |
| ▸ | PTAFR | P25105 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | GMNN | O75496 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sch-37370 SCHEMBL3071641 | 0.90 | PTAFR (1.00) | SLC6A15HRH1FNTAFNTBPTAFR | |
| Sch-37370 SCHEMBL29754039 | 0.90 | PTAFR (1.00) | SLC6A15HRH1FNTAFNTBPTAFR | |
| Sch-37370 SCHEMBL29626524 | 0.90 | PTAFR (1.00) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8879257 | 0.89 | FNTA (0.89) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8878121 | 0.89 | SLC6A15 (0.86) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8891276 | 0.89 | SLC6A15 (0.83) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8880224 | 0.88 | SLC6A15 (1.00) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8889578 | 0.87 | SLC6A15 (0.79) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8877813 | 0.87 | SLC6A15 (0.79) | SLC6A15HRH1FNTAFNTBPTAFR | |
| SCHEMBL8878015 | 0.87 | SLC6A15 (0.86) | SLC6A15HRH1FNTAFNTBPTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295062-B1 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | NYCOMED GMBH (DE) | 2012-08-29 | — | — | EP | claimed |
| EP-1545548-B1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | NYCOMED GMBH (DE) | 2010-06-30 | — | — | EP | claimed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2023-12-12 | — | — | US | disclosed |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) | 2022-06-07 | — | — | US | disclosed |
| US-20210388452-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2021-12-16 | — | — | US | disclosed |
| US-20210317534-A1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2021-10-14 | — | — | US | disclosed |
| US-20210190784-A1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2021-06-24 | — | — | US | disclosed |
| US-11041213-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2021-06-22 | — | — | US | disclosed |
| CN-112645928-A | Method for preparing loratadine II crystal form by continuous flow | 常州大学 | 2021-04-13 | — | — | CN | disclosed |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20090093001-A1 | HIGH CONTENT SCREENING | UNIVERSITY OF NOTTINGHAM | 2009-04-09 | — | — | US | disclosed |
| WO-2006010283-A1 | PREVENTION AND TREATMENT OF THROMBUS FORMATION | Universität Zürich (CH) | 2006-02-02 | — | — | WO | disclosed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | disclosed |
| US-20030035828-A1 | Loratadine transdermal device and methods | PURDUE PHARMA L.P. | 2003-02-20 | — | — | US | disclosed |
| EP-0723538-A1 | TRICYCLIC CARBAMATE COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010515-A1 | TRICYCLIC CARBAMATE COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093001-A1 | HIGH CONTENT SCREENING | CD69, PMAIP1, HCFC1 | SLC6A15 4430/4885HRH1 5/4885FNTA 3654/4885 |
| US-11041213-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, ACP3, MAFK | SLC6A15 3209/4885HRH1 4726/4885FNTA 351/4885 |
| US-20210388452-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | MAFG, ACP3, MAFK | SLC6A15 3209/4885HRH1 4726/4885FNTA 351/4885 |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, ACP3, MAFK | SLC6A15 3209/4885HRH1 4726/4885FNTA 351/4885 |
| US-20210190784-A1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, BRCA1, BCOR | SLC6A15 2433/4885HRH1 3703/4885FNTA 450/4885 |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | MAFG, MAFK, MYCBP | SLC6A15 2730/4885HRH1 4457/4885FNTA 247/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | SLC6A15 2433/4885HRH1 3703/4885FNTA 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.